CC-chemokine binding tick proteins
View Patent ↗A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus . Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
1. An isolated polypeptide comprising:
a) SEQ ID NO: 5;
b) SEQ ID NO: 6;
c) SEQ ID NO: 17;
d) SEQ ID NO: 18; or
e) a fusion protein comprising any one of a), b), c), or d) operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
2. The isolated polypeptide according to claim 1 , wherein said polypeptide comprises SEQ ID NO: 5.
3. The isolated polypeptide according to claim 1 , wherein said polypeptide comprises SEQ ID NO: 6.
4. The isolated polypeptide according to claim 1 , wherein said polypeptide comprises SEQ ID NO: 17.
5. The isolated polypeptide according to claim 1 , wherein said polypeptide comprises SEQ ID NO: 18.
6. The isolated polypeptide according to claim 1 , wherein said polypeptide is a fusion protein comprising SEQ ID NO:5 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
7. The isolated polypeptide according to claim 1 , wherein said polypeptide is a fusion protein comprising SEQ ID NO:6 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
8. The isolated polypeptide according to claim 1 , wherein said polypeptide is a fusion protein comprising SEQ ID NO: 17 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
9. The isolated polypeptide according to claim 1 , wherein said polypeptide is a fusion protein comprising SEQ ID NO:18 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
10. An isolated nucleic acid encoding a polypeptide according to claim 1 .
11. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a polypeptide comprising SEQ ID NO: 5.
12. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a polypeptide comprising SEQ ID NO: 6.
13. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a polypeptide comprising SEQ ID NO: 17.
14. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a polypeptide comprising SEQ ID NO: 18.
15. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a fusion protein comprising SEQ ID NO:5 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
16. The isolated nucleic acid according to claim 10 , said nucleic acid encoding SEQ ID NO:6 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
17. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a fusion protein comprising SEQ ID NO:17 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
18. The isolated nucleic acid according to claim 10 , said nucleic acid encoding a fusion protein comprising SEQ ID NO:18 operably linked to a heterologous sequence selected from: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a signal peptide, an export signal or a tag sequence.
19. The isolated nucleic acid according to claim 10 , wherein said nucleic acid molecule comprises SEQ ID NO: 3.
20. The isolated nucleic acid according to claim 10 , wherein said nucleic acid molecule comprises SEQ ID NO: 4.
21. The isolated nucleic acid according to claim 10 , wherein said nucleic acid molecule comprises SEQ ID NO: 15.
22. The isolated nucleic acid according to claim 10 , wherein said nucleic acid molecule comprises SEQ ID NO: 16.
23. A cloning or expression vector comprising a nucleic acid according to claim 10 .
24. An isolated host cell comprising a cloning or expression vector according to claim 23 .
25. A method of preparing a polypeptide, comprising culturing a host cell according to claim 24 under conditions allowing or promoting expression of the polypeptide.
26. The method according to claim 25 , further comprising purifying the protein.
27. The method according to claim 25 , further comprising formulating the protein in a pharmaceutically acceptable excipient or diluent.
28. A method of inducing an immune response to a polypeptide according to claim 1 comprising administering a composition comprising a polypeptide according to claim 1 to an animal in an amount effective to induce an immune response to said polypeptide.
29. A method of reducing the chemotactic activity of MIP-1α or RANTES comprising contacting MIP-1α or RANTES with a composition comprising a pharmaceutically acceptable carrier or diluent and a polypeptide according to claim 1 .
30. A pharmaceutical composition comprising a polypeptide of claim 1 .